Xeris Pharmaceuticals Inc. (XERS) Misses Q3 EPS by 2c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.03 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• DA Davidson Reiterates Buy Rating on Jack Henry (JKHY)
• H.B. Fuller board rejects Ancora's $1.1B-$1.2B BAS unit bid